Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

Table 2

Longitudinal fluctuations in serum anti-EBNA-1 and anti-VCA IgG levels in relapsing remitting multiple sclerosis (RRMS) patients, considered as a whole, during 21 months of Natalizumab treatment.

Time point (sample)	Serum anti-EBNA-1 IgG levels (AU); median, IQR	Serum anti-VCA IgG levels (AU); median, IQR
( = 16)	273750, 160073–411955	107720, 44682–151729
( = 19)	264992, 133546–372122	82629, 45782–134306
( = 19)	299852, 149020–415994	103548, 52914–158579
( = 19)	272304, 151911–433509	100277, 73889–172901
( = 20)	234446, 159224–369656	112400, 59598–195399
( = 18)	218906, 164613–356031	110428, 88676–276036
( = 19)	230182, 136390–410000	145650, 98579–310823
( = 18)	239703, 163733–366165	115988, 77566–379377

AU = arbitrary units; EBNA-1 = Epstein-Barr nuclear antigen-1; IQR = interquartile range; SD = standard deviation; = baseline; = the 3rd month; = the 6th month; = the 9th month; = the 12th month; = the 15th month; = the 18th month; = the 21st month; VCA = Epstein-Barr viral capsid antigen.